Aptamer-Modified Nb 2 C Multifunctional Nanomedicine for Targeted Photothermal/Chemotherapy Combined Therapy of Tumor
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00433 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Meiqing Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Shanxi Provincial Key Laboratory of Chemical Biosensing, Shanxi Datong University, Datong 037009, China. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Doxorubicin, Nanomedicine, Photothermal Therapy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Shanxi Datong University, Program for the Scientific Activities of Selected Returned Overseas Professionals in Shaanxi Province, Cultivate Scientific Research Excellence Programs of Higher Education Institutions in Shanxi.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The poor delivery efficiency of nanotherapeutic drugs and their potential off-target toxicity significantly limit their effectiveness and extensive application. An active targeting system with high efficiency and few side effects is a promising strategy for tumor therapy. Herein, a multifunctional nanomedicine Nb2C-PAA-DOX@Apt-M (NDA-M) was constructed for targeted photothermal/chemotherapy (PTT/CHT) combined tumor therapy. The specific targeting ability of aptamer could effectively enhance the absorption of nanomedicine by the MCF-7 cell. By employing Apt-M, the NDA-M nanosheets demonstrated targeted delivery to MCF-7 cells, resulting in enhanced intracellular drug concentration. Under 1060 nm laser irradiation, a rapid temperature increase of the NDA-M was observed within the tumor region to achieve PTT. Meanwhile, CHT was triggered when DOX release was induced by photothermal/acid stimulation. The experimental results demonstrated that aptamer-mediated targeting achieved enhanced PTT/CHT efficacy both in vitro and in vivo. Notably, NDA-M induced complete ablation of solid tumors without any adverse side effects in mice. This study demonstrated new and promising tactics for the development of nanomaterials for targeted tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering, Shanxi Provincial Key Laboratory of Chemical Biosensing, Shanxi Datong University, Datong 037009, China.
- School of Medical, Shanxi Datong University, Datong 037009, China.
- Datong Comprehensive Inspection and Testing Center, Datong 037009, China.
- School of Agriculture and Life Science, Shanxi Datong University, Datong 037009, China.
- Department of Energy Chemistry and Materials Engineering, Shanxi Institute of Energy, Taiyuan 030600, China.
ORCID-Profile: Feng Feng
Förderung
- Shanxi Datong University
- Program for the Scientific Activities of Selected Returned Overseas Professionals in Shaanxi Province
- Cultivate Scientific Research Excellence Programs of Higher Education Institutions in Shanxi
- Scientific and Technological Innovation Programs of Higher Education Institutions in Shanxi
- Fundamental Research Program of Datong City
- Fundamental Research Program of Shanxi Province
Zitieren
APA
Liu, M., Zhao, L., Chen, Y., Chen, X., Li, J., Chen, Z., Xu, H., Zhao, Y., Bai, Y., & Feng, F. (2024). Aptamer-Modified Nb 2 C Multifunctional Nanomedicine for Targeted Photothermal/Chemotherapy Combined Therapy of Tumor. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00433
Vancouver
Liu M, Zhao L, Chen Y, Chen X, Li J, Chen Z, et al. Aptamer-Modified Nb 2 C Multifunctional Nanomedicine for Targeted Photothermal/Chemotherapy Combined Therapy of Tumor. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00433
BibTeX
@article{Liu2024,
author = {Liu, Meiqing and Zhao, Lu and Chen, Yuying and Chen, Xiaoliang and Li, Jiang and Chen, Zezhong and Xu, Hui and Zhao, Yingying and Bai, Yunfeng and Feng, Feng},
title = {Aptamer-Modified Nb 2 C Multifunctional Nanomedicine for Targeted Photothermal/Chemotherapy Combined Therapy of Tumor},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00433}
}
EUVIMED